Expression of insulin-like growth factor-I receptor, estrogen receptor α, Bcl-2 and Bax proteins in human breast cancer

Oncology Reports

Volumn 14, Issue 1, 2005, Pages 93-98

  Koda, Mariusz ^a   Przystupa, Wojciech ^a   Jarzabek, Katarzyna ^a   Wincewicz, Andrzej ^a   Kanczuga Koda, Luiza ^a   Tomaszewski, Jakub ^a   Sulkowska, Mariola ^a   Wolczynski, Slawomir ^a   Sulkowski, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bax; Bcl 2; Breast cancer; ER ; IGF IR

Indexed keywords

BAX PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; TUMOR MARKERS, BIOLOGICAL;

EID: 24644461751     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Adams TE, Epa VC, Garrett TP and Ward CW: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093, 2000. (Pubitemid 30598754)
2. Seely BL, Reichart DR, Staubs PA, Jhun BH, Hsu D, Maegawa H, Milarski KL, Saltiel AR and Olefsky JM: Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein. J Biol Chem 270: 19151-19157, 1995.
3. Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5: 95-105, 2000.
4. Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M and Surmacz E: Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors α and β. Horm Metab Res 35: 794-801, 2003. (Pubitemid 38058185)
5. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK and Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13: 787-796, 1999. (Pubitemid 30645331)
6. Guvakova MA, Adams JC and Boettiger D: Functional role of alpha-actinin, PI 3-kinase and MEK 1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci 115: 4149-4165, 2002. (Pubitemid 35446810)
7. Raile K, Hille R, Laue S, Schulz A, Pfeifer G, Horn F and Kiess W: Insulin-like growth factor I (IGF-I) stimulates proliferation but also increases caspase-3 activity, annexin-V binding, and DNA-fragmentation in human MG63 osteosarcoma cells: co-activation of pro- and anti-apoptotic pathways by IGF-I. Horm Metab Res 35: 786-793, 2003. (Pubitemid 38058184)
8. Wu J, Haugk K and Plymate SR: Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. Horm Metab Res 35: 751-757, 2003. (Pubitemid 38058179)
9. Richards RG, diAugustine RP, Petrusz P, Clark GC and Sebastian J: Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA 93: 12002-12007, 1996. (Pubitemid 26347238)
10. Lee AV, Weng CN, Jackson JG and Yee D: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152: 39-47, 1997. (Pubitemid 27026386)
11. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D and Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
12. Surmacz E and Burgaud JL: Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1: 1429-1436, 1995.
13. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R and Santen RJ: Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol Endocrinol 16: 116-127, 2002. (Pubitemid 34044502)
14. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV and Cheng JQ: Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERα) via interaction between ERα and PI3K. Cancer Res 61: 5985-5991, 2001. (Pubitemid 32762525)
15. Reed JC: Mechanisms of apoptosis. Am J Pathol 157: 1415-1430, 2000.
16. Perillo B, Sasso A, Abbondanza C and Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901, 2000. (Pubitemid 30183508)
17. Yao K, Lee ES, Bentrem DJ, England G, Schafer JL O'Regan RM and Jordan VC: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000. (Pubitemid 30305102)
18. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O and Howell A: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116, 2001. (Pubitemid 32744491)
19. Tavassoli FA and Devilee P: Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, 2003.
20. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
21. Koda M, Sulkowski S, Kanczuga-Koda L, Surmacz E and Sulkowska M: Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer. Oncol Rep 11: 753-759, 2004.
22. Koda M, Kanczuga-Koda L, Reszec J, Sulkowska M, Famulski W, Baltaziak M, Kisielewski W and Sulkowski S: Expression of the apoptotic markers in normal breast epithelium, benign mammary dysplasia and in breast cancer. Folia Morphol 63: 337-341, 2004. (Pubitemid 39263796)
23. LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003. (Pubitemid 36588961)
24. Normanno N and Ciardiello F: EGF-related peptides in the pathophysiology of the mammary gland. J Mammary Gland Biol Neoplasia 2: 143-151, 1997. (Pubitemid 127716443)
25. Yang Q, Sakurai T, Jing X, Utsunomiya H, Shan L, Nakamura Y, Nakamura M, Oura S, Suzuma T, Yoshimura G, Umemura T, Kokawa Y and Kakudo K: Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 49: 775-780, 1999. (Pubitemid 29513291)
26. Dorssers LC, van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV and Foekens JA: Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61: 1721-1733, 2001. (Pubitemid 32980504)
27. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P and Hanby A: The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183: 412-417, 1997. (Pubitemid 27509247)
28. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J and Mayer D: Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 89: 506-513, 2000.
29. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R and Glazer PM: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079-3083, 1997. (Pubitemid 27351714)
30. Railo MJ, von Smitten K and Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30: 307-311, 1994. (Pubitemid 24152469)
31. Guvakova MA and Surmacz E: Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231: 149-162, 1997. (Pubitemid 27187524)
32. Parisot JP, Hu XF, deLuise M and Zalcberg JR: Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79: 693-700, 1999. (Pubitemid 29082092)
33. Parrizas M and LeRoith D: Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138: 1355-1358, 1997. (Pubitemid 27089798)
34. Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM and Reusch JE: Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 274: 27529-27535, 1999.
35. Wang L, Ma W, Markovich R, Chen JW and Wang PH: Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 83: 516-522, 1998. (Pubitemid 28411053)
36. Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L and Sulkowski S: Expression of the insulin-like growth factor-I receptor and proapoptotic bax and bak proteins in human colorectal cancer. Ann NY Acad Sci 1030: 377-383, 2004. (Pubitemid 40378936)
37. Koda M, Sulkowska M, Kanczuga-Koda L and Sulkowski S: Expression of the insulin receptor substrate-1 in primary breast cancer and lymph node metastases. J Clin Pathol (In press).
38. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995.
39. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M and Reed JC: Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 3: 199-208, 1997. (Pubitemid 27107295)
40. Yang Q, Sakurai T, Jing X, Utsunomiya H, Shan L, Nakamura Y, Nakamura M, Oura S, Suzuma T, Yoshimura G, Umemura T, Kokawa Y and Kakudo K: Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 49: 775-780, 1999. (Pubitemid 29513291)
41. Maciorowski Z, Klijanienko J, Padoy E, Mosseri V, Dieras V, El-Naggar AK, Chevillard S and Vielh P: Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomas. Cytometry 42: 264-269, 2000.
42. Martinez-Arribas F, Nunez-Villar MJ, Lucas AR, Sanchez J, Tejerina A and Schneider J: Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients. Anticancer Res 23: 565-568, 2003. (Pubitemid 36358452)
43. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK and Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82: 1296-1302, 1998. (Pubitemid 28155391)
44. Surmacz E: Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22: 6589-6597, 2003.